Skip to main content
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · XENE ISIN · CA98420N1050 LEI · 549300XV44Q9Z1MIPQ03 US Manufacturing
Open in API
Filings indexed 746 across all filing types
Latest filing 2020-03-11 Regulatory Filings
Country CA Canada
Listing US XENE

About Xenon Pharmaceuticals Inc.

https://www.xenon-pharma.com/

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to the discovery, clinical development, and commercialization of therapeutics for neurological and psychiatric disorders. The company leverages its expertise in human genetics and a deep understanding of ion channel biology to develop medicines that modulate ion channels, targeting the central and peripheral nervous systems. Its late-stage pipeline includes azetukalner, an investigational candidate being developed for the treatment of epilepsy and depression.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions the announcement of meeting, record date, and other information related to the 2020 annual meeting of shareholders, but it does not contain detailed financial statements or comprehensive report content. The document is relatively short (3336 characters) and includes a reference to a SEDAR filing as an exhibit, indicating that the detailed report is filed elsewhere. This fits the pattern of a Regulatory Filing (RNS) rather than a full Annual Report (10-K) or other detailed report. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2020-03-11 English
S-8
Capital/Financing Update Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Xenon Pharmaceuticals Inc. on March 9, 2020. It registers additional common shares reserved for issuance under the company's 2014 Equity Incentive Plan. The document includes details about the securities to be registered, incorporation by reference of prior filings including the 10-K annual report, and exhibits such as the equity incentive plan and share option agreements. Form S-8 is specifically used for registering securities to be offered under employee benefit plans and is a capital/financing related filing. It is not an annual report, earnings release, or other financial report. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the registration statement itself, not just an announcement or certification.
2020-03-09 English
10-K
Annual Report FY 2019
2020-03-09 English
Q4 EARNINGS RELEASE
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 9, 2020, reporting the company's financial results for the year ended December 31, 2019. It specifically states that the financial results are announced via a press release attached as Exhibit 99.1. The document itself is short (3456 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis. According to the 'Menu vs Meal' rule, such a document that announces or furnishes a press release of earnings results without including the full financial data should be classified as an Earnings Release (ER).
2020-03-09 English
Regulatory Filings 2020
Regulatory Filings
2020-02-27 English
AMENDMENT NO. 8 TO THE SCHEDULE 13D
Major Shareholding Notification
2020-02-14 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.